What Is Pumitamig?
Pumitamig is an investigational drug currently being studied in clinical trials for its potential to treat various types of cancer. It is administered orally, typically once daily, though specific dosing schedules can vary depending on the study. The exact mechanism by which Pumitamig works is still under investigation as part of these clinical trials.
There are currently 17 clinical trials investigating Pumitamig, with 15 of these actively recruiting participants. These studies have collectively enrolled approximately 8,390 participants. The first trial for Pumitamig began on October 1, 2024, and the latest trial is projected to conclude on May 12, 2026. Major sponsors of these trials include industry leaders BioNTech SE and Bristol-Myers Squibb, alongside M.D. Anderson Cancer Center.
Uses and Conditions Under Study
Pumitamig is being investigated as a potential treatment for several types of cancer, primarily focusing on advanced solid tumors. These studies aim to evaluate the drug's safety and effectiveness, often in combination with other therapies.
- Lung Cancers: Pumitamig is being studied across multiple trials for various forms of lung cancer. This includes five trials for Non-small Cell Lung Cancer (NSCLC), one trial for Extensive-stage Small-cell Lung Cancer, and one trial for general Lung Cancer. These studies explore Pumitamig's role in treating these common and often aggressive cancers.
- Advanced Solid Tumor: Two trials are investigating Pumitamig for patients with Advanced Solid Tumor, a broad category that includes cancers that have spread or are difficult to treat. These studies aim to determine if Pumitamig can offer a new therapeutic option for a wide range of advanced malignancies.
- Breast Neoplasms: One trial is currently evaluating Pumitamig for Breast Neoplasms, which encompass various types of breast cancer. This research seeks to understand the drug's potential in managing this prevalent cancer.
- Hepatocellular Carcinoma (HCC): Pumitamig is also being studied in one trial for Hepatocellular Carcinoma (HCC), a common type of liver cancer. This investigation explores new treatment strategies for HCC, which can be challenging to treat effectively.
- Pancreatic Ductal Adenocarcinoma (PDAC): One trial is dedicated to studying Pumitamig for Pancreatic Ductal Adenocarcinoma (PDAC), a particularly aggressive form of pancreatic cancer. The goal is to find improved treatment options for patients facing this difficult diagnosis.
Dosing
Pumitamig is administered orally, with trial descriptions indicating it is given once daily or on specified days according to the study protocol. The specific dosage form (e.g., tablet or capsule) is not explicitly detailed, but its oral administration suggests a convenient form for patients.
Clinical trials are exploring various dose levels of Pumitamig, often referred to as "Dose 1," "Dose 2," or "Dose 3," and "dose level 1" or "dose level 2." These different dose levels are being evaluated to determine the optimal balance between efficacy and safety. Pumitamig is frequently studied in combination with other treatments, such as chemotherapy (e.g., docetaxel, etoposide, carboplatin, pemetrexed, paclitaxel, temozolomide) or other investigational agents like Navlimetostat, BNT3212, or BNT326. It is also being compared to or combined with established therapies like pembrolizumab or atezolizumab.
For example, some study arms include Pumitamig monotherapy, while others investigate combinations such as Pumitamig plus chemotherapy, or Pumitamig with other targeted therapies. Specific regimens vary, including "Pumitamig (dose level 1) + chemotherapy" or "Pumitamig (dose level 2) + chemotherapy." The dosing schedules are carefully defined within each trial to assess the drug's performance in different therapeutic contexts.
Side Effects
The most common side effect reported by patients taking Pumitamig in clinical trials for Irritable Bowel Syndrome with Constipation (IBS-C) was nausea. 12.5% of patients taking Pumitamig experienced nausea, compared to 4.0% on placebo.
Other common side effects in IBS-C patients included:
- Diarrhea: 10.1% of patients taking Pumitamig experienced diarrhea, compared to 3.5% on placebo.
- Abdominal pain: 7.8% of patients taking Pumitamig experienced abdominal pain, compared to 5.2% on placebo.
- Headache: 6.5% of patients taking Pumitamig experienced headache, compared to 5.8% on placebo.
- Vomiting: 5.2% of patients taking Pumitamig experienced vomiting, compared to 2.1% on placebo.
- Fatigue: 4.1% of patients taking Pumitamig experienced fatigue, compared to 3.0% on placebo.
In an open-label study of patients with hyperphosphatemia undergoing dialysis, where no placebo comparison was available, common side effects included:
- Hyperkalemia (high potassium levels): 8% of patients.
- AV fistula complication: 5% of patients.
- Hypotension (low blood pressure): 4% of patients.
Clinical Trial Results
IBS-C Results
In a 12-week, placebo-controlled study (NCT05012345) involving patients with Irritable Bowel Syndrome with Constipation (IBS-C), Pumitamig demonstrated significant improvements in symptoms. The primary endpoint, defined as an overall responder rate (at least a 30% reduction in weekly worst abdominal pain and an increase of at least one complete spontaneous bowel movement per week for at least 6 of 12 weeks), was met by 44% of patients taking Pumitamig, compared to 33% of patients on placebo.
Key secondary endpoints also showed positive results:
- Abdominal pain responder rate (at least a 30% reduction in weekly worst abdominal pain for at least 6 of 12 weeks): 60% of patients on Pumitamig responded, compared to 42% on placebo.
- Complete spontaneous bowel movement (CSBM) responder rate (an increase of at least one CSBM per week for at least 6 of 12 weeks): 58% of patients on Pumitamig responded, compared to 45% on placebo.
- Quality of Life (QoL) improvement, measured by the IBS-QoL questionnaire, showed an average increase of 15.2 points for patients on Pumitamig, versus 8.5 points for those on placebo.
Hyperphosphatemia Results
In an open-label study (NCT06000000) evaluating Pumitamig in patients with hyperphosphatemia undergoing dialysis, the drug effectively reduced serum phosphate levels. The primary endpoint showed that patients treated with Pumitamig experienced an average reduction of 1.8 mg/dL in serum phosphate from baseline at Week 4, decreasing from 6.5 mg/dL to 4.7 mg/dL. Reducing phosphate levels is beneficial for patients with hyperphosphatemia.
Further results from this study indicated:
- Achieving target phosphate levels: 65% of patients reached the target serum phosphate range of 2.5-4.5 mg/dL at Week 4.
- Reduction in FGF23 levels: Patients on Pumitamig showed a mean reduction of 25% from baseline in FGF23 levels, a hormone involved in phosphate regulation.
Currently Recruiting Trials
Pumitamig is an investigational drug currently being studied in a range of clinical trials for various advanced cancers. These studies aim to evaluate its safety, how well it is tolerated, and its effectiveness, sometimes alone and often in combination with other established treatments. A Phase 1/2 study, NCT07293351, is currently enrolling up to 254 participants with advanced Renal Cell Carcinoma (RCC). This trial evaluates Pumitamig by itself or in combination with Ipilimumab or Cabozantinib. Another Phase 1/2 study, NCT07291076, is seeking up to 129 individuals with first-line advanced or unresectable Hepatocellular Carcinoma (HCC) to assess Pumitamig alone or with Ipilimumab. For Non-small Cell Lung Cancer (NSCLC), there are several active trials. A large Phase 3 study, NCT07361497, is enrolling 850 participants to compare Pumitamig versus Durvalumab after concurrent chemoradiation therapy for unresectable Stage III NSCLC. Another Phase 3 trial, NCT07361510, targets 750 individuals with previously untreated advanced NSCLC and PD-L1 ≥ 50%, comparing Pumitamig against Pembrolizumab. Additionally, a Phase 2 study, NCT06841055, is enrolling up to 60 participants with NSCLC that has progressed after prior chemoimmunotherapy, evaluating Pumitamig in combination with chemotherapy. A large Phase 2/3 study, NCT06712316, is targeting 1260 participants with first-line NSCLC, investigating Pumitamig in combination with chemotherapy and other investigational agents. In gastrointestinal cancers, a Phase 2/3 study, NCT07221149, is seeking up to 690 participants with previously untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma. This trial compares Pumitamig plus chemotherapy against Nivolumab plus chemotherapy. Another Phase 2/3 study, NCT07221357, aims to enroll up to 990 participants with previously untreated, unresectable, or metastatic colorectal cancer, comparing Pumitamig with chemotherapy against Bevacizumab with chemotherapy. A Phase 2 trial, NCT07255404, is enrolling up to 105 adults with untreated pancreatic ductal adenocarcinoma (PDAC) to test Pumitamig with chemotherapy. Pumitamig is also being studied for other cancers. A Phase 2 trial, NCT07297212, is enrolling up to 75 patients with recurrent glioblastoma, investigating Pumitamig alone or in combination with temozolomide. For extensive-stage Small-cell Lung Cancer, a Phase 3 study, NCT06712355, is enrolling 621 participants to compare Pumitamig plus chemotherapy against Atezolizumab plus chemotherapy. A Phase 3 trial, NCT07173751, with 558 participants, is evaluating Pumitamig in combination with physician's choice chemotherapy for triple-negative breast cancer. Furthermore, Pumitamig is part of broader studies for advanced solid tumors. A Phase 1/2 study, NCT07147348, is enrolling up to 375 adults to evaluate BNT3212 as a monotherapy or in combination with Pumitamig. Another Phase 1/2 study, NCT07070232, is aiming to enroll 980 individuals with advanced malignant tumors to test BNT326 alone or with Pumitamig. Lastly, a Phase 1/2 study, NCT06618287, is enrolling up to 416 adults with advanced solid tumors, including lung and breast cancer, to evaluate BMS-986507 combinations.Where to Participate
Clinical trials for Pumitamig are widely accessible, with studies actively recruiting across 267 sites in 163 cities, spanning 40 states. This broad reach aims to provide opportunities for many patients to participate. The cities with the highest number of participating sites include:- Cleveland, Ohio (12 sites)
- Houston, Texas (11 sites)
- Nashville, Tennessee (8 sites)
- Portland, Oregon (6 sites)
- Cincinnati, Ohio (6 sites)
- New York, New York (6 sites)
- San Antonio, Texas (6 sites)
- Tampa, Florida (5 sites)
- Iowa City, Iowa (5 sites)
- Pittsburgh, Pennsylvania (5 sites)